Martin Kolb, MD-PhD
- Associate Professor, Division of Respirology, Department of Medicine and Pathology & Molecular Medicine; St. Joseph's Healthcare, Firestone Institute for Respiratory Health
- Specialty clinic for interstitial lung disease and lung fibrosis
- Inpatient service for general internal medicine, respirology, and ICU
- Consulting service
Education and Professional standing:
- M.D., University of Würzburg, Germany, 1991
- Residency, Anatomical Pathology, University Erlangen/Nürnberg
- Residency, General Internal and Respiratory Medicine, University of Würzburg, Germany, 1993
- Postdoctoral research fellowship in pulmonary fibrosis with Dr. Jack Gauldie, McMaster University, 1999
- Habilitation for Internal Medicine (PhD equivalent ), Germany, 2003
- Assistant Professor, Department of Pathology, McMaster, 2003
- Department of Medicine and the Firestone Institute for Respiratory Health, 2004
- Research Director, Firestone Institute for Respiratory Health, 2009
- Director, Division of Respirology, Department of Medicine, McMaster University 2013
Dr. Kolb's major research area is focused on mechanisms of lung injury, repair and fibrosis, particularly in Idiopathic Pulmonary Fibrosis (IPF). He has a strong interest in growth factor biology (e.g. TGFβ and IL-1), extracellular matrix, and mesenchymal cell progenitors (mesenchymal stem cells and fibrocytes). In his lab he uses a variety of animal models to study disease mechanisms and also the efficacy of novel drugs in the preclinical setting. Further, Dr. Kolb leads activities in biomarker development for lung fibrosis and he participates as Principal Investigator and Steering Committee members in numerous clinical trials on interstitial lung disease. Dr. Kolb has over 100 peer-reviewed publications in journals such as New England Journal of Medicine, Journal of Clinical Investigation, American Journal of Pathology, American Journal of Respiratory and Critical Care Medicine, Journal of Immunology, European Respiratory Journal and many others. He is/was funded by CIHR, NIH, CFI, OTS and different Pharma companies over the years. He has received career awards from the Parker B. Francis Families Foundation, the Department of Medicine at McMaster and the New Investigator Award from the Canadian Institute for Health Research.
Dr. Kolb looks after several hundred patients with interstitial lung disease in his specialty clinic and also practices in General Respirology. He is medical staff at St. Joseph's Healthcare Hamilton for Respirology and General Internal Medicine. Clinic bookings can be made through extension x35003.
- Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. N Engl J Med. 2014 May 29;370(22):2071-82.
- Bellaye PS, Wettstein G, Burgy O, Besnard V, Joannes A, Colas J, Causse S, Marchal-Somme J, Fabre A, Crestani B, Kolb MRJ, Gauldie J, Camus P, Garrido C, Bonniaud P. The small heat shock protein αB-crystallin is essential for the nuclear localization of Smad4: impact on pulmonary fibrosis. J Pathol 2014; 232: 458–472.
- Wettstein G, Bellaye PS, Kolb MRJ, Hammann A, Crestani B, Soler P, Marchal-Somme J, Hazoume A, Gauldie J, Gunther A, Micheau O, Gleave M, Camus P, Garrido C, Bonniaud P. Inhibition of HSP27 blocks fibrosis development and EMT features by promoting snail degradation. FASEB J. 2013 Apr;27(4):1549-60
- Hanumegowda C, Farkas L, Kolb MRJ. Angiogenesis in Pulmonary Fibrosis-Too much or not enough? Chest 2012 July 1;142(1):200-7
- Farkas L, Gauldie J, Voelkel N F, Kolb MRJ. Pulmonary Hypertension and Idiopathic Pulmonary Fibrosis-A Tale of Angiogenesis, Apoptosis and Growth Factors. Am J Respir Cell Mol Biol. 2011 Jul;45(1):1-15
- Farkas L, Ask K, Möller A, Farkas D, Margetts PJ, Gauldie J, Inman M, Kolb MRJ. VEGF-mediated angiogenesis ameliorates pulmonary hypertension in an animal model of lung fibrosis. J Clin Invest 2009;119(5):1298-311
- Möller A, Gilpin SE, Ask K, Cox G, Cook DJ, Gauldie J, Margetts PJ, Farkas L, Dobranowski J, Boylan C, O'Byrne PM, Strieter RM, Kolb MRJ. Circulating Fibrocytes are an indicator for poor prognosis in Idiopathic Pulmonary Fibrosis. Am J Resp Crit Care Med 2009; 179(7):588-94